Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could removing certain immune cells prevent a deadly transplant complication?

NCT ID NCT03779854

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 28 times

Summary

This study tests whether removing a specific type of immune cell (naive T cells) from donor stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body after a stem cell transplant. The trial aims to see if this approach is safe and effective, with about 68 participants receiving either the modified cells or standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Healthcare of Atlanta

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30329, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Children's Hospital of Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Children's Hospital of Pittsburgh of UPMC

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

    Contact Email: •••••@•••••

    Contact

  • Children's National Medical Center

    WITHDRAWN

    Washington D.C., District of Columbia, 200100, United States

  • Cleveland Clinic Foundation

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber / Boston Children's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Oregon Health and Science University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UH Rainbow Babies and Children's Hospital (University Hospitals Cleveland Medical Center)

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Iowa/Holden Comprehensive Cancer Center

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute leukemia acute leukemia of ambiguous lineage acute lymphoblastic leukemia acute myeloid leukemia acute undifferentiated leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm Burkitt lymphoma CD4+/CD56+ hematodermic neoplasm chronic monocytic leukemia GATA2 Deficiency lymphoblastic lymphoma mast cell leukemia mixed phenotype acute leukemia myelodysplastic syndrome with excess blasts myelodysplastic syndrome with excess blasts-1 myeloid leukemia Myeloproliferative Disorders myeloproliferative neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.